Publicaties 1981 – 1995
1. Wolffenbuttel BHR, Verdouw PD, Hugenholtz PG. Immediate and two year prognosis after acute myocardial infarction: prediction from non invasive as well as invasive parameters in the same individuals. Eur Heart J 1981; 2: 375-87.
2. Verdouw PD, Wolffenbuttel BHR, ten Cate FJ. Nifedipine with and without propranolol in the treatment of myocardial ischemia: effect on ventricular arrhythmias and recovery of regional wall function. Eur Heart J 1983; 4 (suppl. C): 101-8.
3. Verdouw PD, Wolffenbuttel BHR, Giessen WJ vd. Domestic pigs in the study of myocardial ischemia. Eur Heart J 1983; 4 (suppl. C): 61-7.
4. Wolffenbuttel BHR, Hugenholtz PG, Verdouw PD, Lubsen J. Prediction of survival after acute myocardial infarction from hemodynamic parameters measured on admission. In: The first year after myocardial infarction, editor: H.E. Kulbertus.
5. Wolffenbuttel BHR, Verdouw PD, Scheffer MG, Bom HPA, Bijleveld RE, Hugenholtz PG. The significance of haemodynamic variables in coronary care unit for prediction of survival after acute myocardial infarction. Br Heart J 1983; 50: 266-72.
6. Verdouw PD, Wolffenbuttel BHR. Heat stroke during physical exercise. Ned Tijdschr Geneeskd 1983; 127: 79-80.
7. Verdouw PD, Wolffenbuttel BHR. The effect of felodipine on ventricular fibrillation after coronary artery ligation in the anaesthetized pig. Br J Pharmacol 1983; 79: 6-8.
8. Verdouw PD, Wolffenbuttel BHR, Scheffer MG. Cardiovascular effects of the calmodulin inhibitor felodipine. Naunyn Schmiedeberg’s Archives of Pharmacology 1983; 323: 350-4.
9. Wolffenbuttel BHR, Verdouw PD. Nifedipine and myocardial performance in the presence and absence of beta blockade with propranolol. Arch Intern Pharmacodyn et Therapie 1983; 266: 83-92.
10. Verdouw PD, Wolffenbuttel BHR, ten Cate FJ. Experimental evidence for a role of calcium antagonists in the prevention and treatment of myocardial ischemia. Progress in Pharmacol 1985; 5: 35-46.
11. Wolffenbuttel BHR, Weber RFA, Kho GS. Pyopneumothorax: a rare complication of Wegener’s granulomatosis. Eur J Resp Dis 1985; 67: 223-7.
12. Verdouw PD, Hartog JM, Wolffenbuttel BHR, et al. Intracoronary and intravenous effects of calcium antagonists on cardiac efficiency without and with beta adrenoceptor blockade. In: Lichtlen PR, ed. New therapy of ischemic heart disease and hypertension. Amsterdam, Geneva, Hongkong, London, Princeton, Tokyo: Excerpta Medica 1986; 347-56.
13. Wolffenbuttel BHR, Toorenenbergen AW v, Blijenberg BG, Verschoor L, Weber RFA. The determination of urinary albumin excretion to detect early nephropathy in patients with diabetes mellitus. Ned Tijdschr Geneesk 1986; 130: 1995-1998.
14. Wolffenbuttel BHR, Baggen MGA, Verschoor L. The effects of regular exercise on lipid metabolism, overweight and atherosclerosis. Hartbulletin 1986; 17: 149-154.
15. Verschoor L, Wolffenbuttel BHR, Weber RFA. Betablockade and carbohydrate metabolism. Theoretical aspects and clinical implications. J Cardiovasc Pharmacol 1986; 8 (suppl.II): S92-95.
16. Wolffenbuttel BHR, Weber RFA, Prins MEF, Verschoor L. Premature ovarian failure and autoimmune hypothyroidism in the absence of Addison’s disease. Neth J Med 1987; 30: 128-134.
17. Groen JN, Wolffenbuttel BHR, Baggen MGA, Stallaert RALM, Prins MEF, Birkenhäger JC. Tuberculosis of the thyroid gland. Neth J Med 1988; 32: 199-203.
18. Wolffenbuttel BHR, Vreeburg J. Insulin therapy does not diminish beta-cell damage in the neonatal streptozotocin-injected rat. Diabetes Research 1988; 9: 77-79.
19. Wolffenbuttel BHR. DIABASE – a database for diabetes mellitus. Diabetes Praktijk 1988;1:6-7.
20. Nieuwenhuijzen Kruseman AC, Degenaar CP, Wolffenbuttel BHR. The value of the use of Micro-Bumintest tablets for the detection of micro-albuminuria in diabetic patients. Ned Tijdschr Geneeskd 1989; 133: 40-41.
21. Wolffenbuttel BHR, Weber RFA, Koetsveld PM van, Verschoor L. Limitations of dietary therapy in the treatment of patients with type II diabetes mellitus. Int J Obesity 1989; 13: 173-182.
22. Wolffenbuttel BHR. Combined use of insulin and oral hypoglycaemic agents in the treatment of patients with diabetes mellitus. Eur J Int Med 1989; 1: 89-95.
23. Wolffenbuttel BHR, Weber RFA, Van Koetsveld PM, Weeks L, Verschoor L. A randomized cross-over study of sulfonylurea and insulin treatment in patients with non-insulin-dependent diabetes mellitus failing on diet therapy. Diabetic Medicine 1989; 6: 520-525.
24. Wolffenbuttel BHR, Nieuwenhuijzen Kruseman AC. Diabetes mellitus and the kidney. Diabetes Praktijk 1989; 2: 10-11.
25. Kingma PJ, Simons JPFHA, Nieuwenhuijzen Kruseman AC, Wolffenbuttel BHR. Calcium entry blockers and their effects on glucose metabolism. Neth J Med 1990; 36: 32-38.
26. Wolffenbuttel BHR, Weber RFA, Weeks L, Koetsveld PM van, Verschoor L. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas. Diabetes Research 1990; 13: 79-84.
27. Wolffenbuttel BHR, Van Ouwerkerk BM, Veldhuijzen BFE, Geelhoed-Duijves¬tijn PHLM, Jakobsen G, Van Doorn LG. Comparative effects of two different multiple injection regimens on blood glucose control and patient acceptance in type 1 diabetes. Diabetic Medicine 1990; 7: 695-699.
28. Van Deursen RTAM, Nieuwenhuijzen Kruseman AC, Degenaar CP, Wolffenbut¬tel BHR. The effects of a the cholesterol synthesis inhibitor simvastatin in patients with hypercholeste¬rolaemia with and without diabetes mellitus. Ned Tijdschr Geneeskd 1990; 134: 2142-2146.
29. Sneeuw KCA, Wolffenbuttel BHR, Nieuwenhuijzen Kruseman AC, Visser APh. Evaluation of the education course ‘Diabetes Cirkel’. Gedrag en Gezondheid 1990; 18: 237-240.
30. Wolffenbuttel BHR, Rondas-Colbers GJWM, Menheere PPCA, Sels JPJE, Nieuwenhuijzen Kruseman AC. The effects of insulin therapy combined with glibenclamide on glucose- and lipid metabolism in patients with type 2 diabetes mellitus. Ned Tijdschr Geneeskd 1991; 135: 1080-1084.
31. Sels JPJE, Postmes ThJL, Wolffenbuttel BHR, Nieuwen¬huijzen Kruseman AC. Dietary fibre in the management of diabetes mellitus: a review. Neth J Med 1991; 38: 265-277.
32. Wolffenbuttel BHR. Combination of insulin and glibenclamide in NIDDM patients. Ned Tijdschr Chronische Ziekten 1991; 1: 16-18.
33. Wolffenbuttel BHR, Van Vliet S, Knols AJF, Slits WLH, Sels JPJE, Nieuwenhuijzen Kruseman AC. Clinical characteristics and management of diabetic patients residing in a nursing home. Diabetes Res & Clin Pract 1991; 13: 199-206.
34. Wolffenbuttel BHR, Storms GEMG, Rinck R. DIABASE: a compact diabetes database program. Diabetes Nutrition Metabolism 1991; 4 (suppl. 1): 73-76
35. Wolffenbuttel BHR, Sels JPJE, Verhoeven S, Nieuwenhuijzen Kruseman AC. Diabetes control and secondary complications in type 2 diabetic patients. Ned Tijdschr Geneeskd 1991; 135: 2387-2391.
36. Wolffenbuttel BHR, Sels JPJE, Jungbauer FHW, Menheere PPCA, Nieuwenhuijzen Kruseman AC. The value of fasting blood glucose and serum fructosamine in the evaluation of metabolic control in NIDDM patients. Diabetes Nutrition & Metabolism 1991; 4: 297-303
37. Peltenburg HG, Tiebosch A, Van den Berg-Loonen PM, Van Ballegooie E, Leunissen KML, Wolffenbuttel BHR, Wijnen R, Kootstra G, Van Hooff JP. A positive T cell crossmatch and accelerated acute rejection of a pancreas-spleen allograft. Transplantation 1992; 53: 226-228.
38. Wolffenbuttel BHR, Sels JPJE, Heesen BJ, Menheere PPCA, Nieuwenhuijzen Kruseman AC. The effects of dietary fibre and insulin treatment on plasma lipids and lipoprotein(a) in patients with type 2 diabetes mellitus. Ned Tijdschr Geneeskd 1991; 136: 739-742
39. Peltenburg HG, Wolffenbuttel BHR, Booster MH, Menheere PPCA, Leunissen KML, Kootstra G, Van Hooff JP. Reperfusion injury of pancreas allografts: relation to islet cell function. Transplant Int 1992; 5 (suppl. 1): S270-271.
40. Wolffenbuttel BHR, Menheere PPCA, Nijst L, Rondas-Colbers GJWM, Nieuwenhuijzen Kruseman AC. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: evidence for glucose toxicity. Neth J Med 1992; 40: 277-282.
41. Wolffenbuttel BHR, Sels JPJE, Heesen BJ, Menheere PPCA, Nieuwenhuijzen Kruseman AC. Lipoprotein(a) levels and diabetes control. Diabetes Care 1992; 15: 941.
42. Wolffenbuttel BHR, Van Kimmenade R, Sels JPJE, Nieuwenhuijzen Kruseman. Prevalence of diabetic complications related to albuminuria in patients with non-insulin-dependent diabetes mellitus (NIDDM) treated in a hospital clinic. Nutr Metab Cardiovasc Dis 1992; 2: 63-68.
43. Sels JPJE, de Bruin H, Camps MHTA, Postmes ThJL, Men¬heere PPCA, Wolffen¬buttel BHR, Nieuwenhuijzen Kruseman AC. Absence of guar efficacy in complex spaghetti meals on postprandial glucose and C-peptide levels in healthy control and non-insulin dependent diabetes mellitus subjects. Horm Metab Res 1992; suppl. 26: 52-58.
44. Nieuwenhuijzen Kruseman AC, Van den Berg BW, Degenaar CP, Wolffenbuttel BHR. Screening for microalbuminuria with Micro-Bumin test tablets and albumin/creatinin ratio. Horm Metab Res 1992; suppl. 26: 71-75.
45. Wolffenbuttel BHR. Epidemiology of diabetes mellitus. Tijdschr Huisartsgeneeskunde 1992; 9 (suppl.): 3-8
46. Oranje WA, Wolffenbuttel BHR. Low cholesterol and excess mortality: a real relationship? Neth J Med 1993; 42: 89-92.
47. Wolffenbuttel BHR, Van Haeften TW. Non-insulin-dependent diabetes mellitus: defects in insulin secretion. Eur J Clin Invest 1993; 23: 69-79
48. Wolffenbuttel BHR, Leurs PB, Sels JPJE, Rondas-Colbers GWJM, Menheere PPCA, Nieuwenhuijzen Kruseman AC. Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels. Diabetic Med 1993; 10: 427-430.
49. Wolffenbuttel BHR, Huijberts MSP. Aminoguanidine, a potential drug for the treatment of diabetic complications. Neth J Med 1993; 42: 205-208
50. Huijberts MSP, Wolffenbuttel BHR, Crijns FRL, Nieuwenhuijzen Kruseman AC, Bemelmans M, Van Essen H, Smits J, Struyker Boudier HAJ. ACE-inhibition reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes. Eur J Pharmacol 1993; 240: 207-212
51. Heesen BJ, Sels JPJE, Menheere PPCA, Jäckle-Beckers SEC, Nieuwenhuijzen Kruseman AC, Wolffenbuttel BHR. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993; 23: 580-584
52. Wolffenbuttel BHR, Nijst L, Sels JPJE, Menheere PPCA, Müller PG, Nieuwenhuijzen Kruseman AC. Safety and efficacy of a new oral hypoglycemic agent, AG-EE 623 ZW, in sulfonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-116
53. Wolffenbuttel BHR, Drossaert CHC, Visser APh. Determinants of the behaviour ‘injecting insulin’ in elderly patients with type 2 diabetes mellitus. Patient Educ Counseling 1993; 22: 117-125
54. Wolffenbuttel BHR. Type 2 diabetes mellitus – aspects of pathogenesis and treatment (review). Neth J Med 1993; 41:187-199
55. Huijberts MSP, Wolffenbuttel BHR, Struyker Boudier HAJ, Crijns FRL, Nieuwen¬huijzen Kruseman AC, Poitevin P, Lévy BI. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-1411
56. Sels JPJE, Postmes ThJL, Nieman F, Ebert R, Wolffenbuttel BHR, Nieuwenhuijzen Kruseman AC. Effects of guar bread in type 1 and type 2 diabetes mellitus. Eur J Int Med 1993; 4: 193-200
57. Wolffenbuttel BHR, Huijberts MSP, Heesen BJ, Leurs PB, Nieuwenhuijzen Kruseman AC. Goede instelling van diabetes mellitus verkleint de kans op diabetische complicaties. Ned Tijdschr Geneeskd 1993; 137: 2179-2183
58. Wolffenbuttel BHR. The DCCT: “metabolic control matters”. Neth J Med 1993; 43: 241-245
59. Hasan K, Heesen BJ, Corbett JA, McDaniel ML, Chang K, Allison W, Wolffenbuttel BHR, Williamson JR, Tilton RG. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993; 249: 101-106
60. Huijberts MSP, Wolffenbuttel BHR, Crijns FRL, Nieuwenhuijzen Kruseman AC, Bemelmans M, Struyker Boudier HAJ. Aminoguanidine reduces regional albumin clearance, but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 1994; 37: 10-14
61. Sels JPJE, Kingma PJ Wolffenbuttel BHR, Menheere PPCA, Branolte JH, Nieuwenhuijzen Kruseman AC. Effect of miglitol (BAY M-1099) on fasting blood glucose in type 2 diabetes. Neth J Med 1994; 44: 198-201
62. Van Haeften TW, Wolffenbuttel BHR. Zelfcontrole van bloedglucose: op welke tijden meten en waarom? EADE Nieuwsbrief 1994; 9: 24-26
63. Wolffenbuttel BHR. Diabetes mellitus. Tijdschr Therapie Geneesmiddel & Onderzoek 1994; 19: 2-4
64. Leurs PB, Van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor (TFPI) activity is increased in patients with IDDM. Diabetes 1995; 44: 80-84
65. Wolffenbuttel BHR, Van Haeften TW. Pharmacological prevention of diabetic complications. Drugs 1995; 50: 263-288
66. Wolffenbuttel BHR. Risk factors for coronary artery disease in NIDDM. Int Diab Mon 1995; 7: 6-7
67. Wolffenbuttel BHR. Barriers to adequate insulin therapy in diabetes. Int Diab Mon 1995; 7: 18-20
68. Van Haeften TW, Wolffenbuttel BHR. Insuline injectie techniek? EADE Nieuwsbrief 1995;
69. Mulder WJ, Lavrijssen AT, Wolffenbuttel BHR, Fiolet JFBM. Behandeling van hypercholesterolemie bij ouderen. Ned Tijdschr Geneeskd 1995; 139: 821-825
Recente reacties